Indexado en

Licencia y uso

Citaciones

Cited 26 times in

Cited 24 times in

Altmetrics

Grant support

Supported by the grant From the theory to the practice of the Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). The English Language edition was supported by Cosmos Specialized Services (Madrid, Spain).; F. Bermejo has served as a speaker and consultant from MSD and Abbvie. A. Algaba reports grants from MSD. J. P. Gisbert has served as a speaker, a consultant, and advisory member for or has received research funding from MSD, Abbvie, Hospira, Kern Pharma, Takeda, Janssen, Pfizer, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Chiesi, Casen Fleet, Gebro Pharma, Otsuka Pharmaceutical, and Vifor Pharma. The remaining authors have no conflict of interest to disclose.

Análisis de autorías institucional

Compartir

Evaluation of the Quality of Semen and Sexual Function in Men with Inflammatory Bowel Disease

Publicado en:Inflammatory Bowel Diseases. 23 (7): 1144-1153 - 2017-07-01 23(7), DOI: 10.1097/MIB.0000000000001081

Autores: Valer, P; Algaba, A; Santos, D; Fuentes, ME; Nieto, E; Gisbert, JP; López, P; Quintanilla, E; García-Alonso, FJ; Guerra, I; Páez, A; Bermejo, F

Afiliaciones

Resumen

Background: Data on fertility rates and medication safety in men with inflammatory bowel disease (IBD) are limited. The aim of this study was to evaluate whether there is a seminal alteration in patients with IBD and, if so, to evaluate the mechanisms that may play a role according to what has been described in the literature. Its secondary aim was to evaluate the impact on male sexual function of IBD. Methods: Multicenter, cross-sectional, case series study comparing men with IBD and control subjects. Semen analysis was performed according to the recommendations of World Health Organization. The impact on male sexual function was evaluated with the International Index of Erectile Function questionnaire. Results: On multivariate analysis, patients with Crohn's disease had lower sperm concentrations compared with those with ulcerative colitis (median [interquartile range], 34.5 [19.2-48] versus 70 [34.5-127.5], P = 0.02) and lower seminal zinc levels (mean +/- SD, 1475 +/- 235 mmol/L versus 2221 +/- 1123 mmol/L, P = 0.04). Patients with Crohn's disease on anti-tumor necrosis factor treatment had better progressive motility (mean +/- SD, 56.7 +/- 17.7 versus 35.1 +/- 22.1, P = 0.01) and sperm morphology (14.4 +/- 7.1 versus 7.6 +/- 4.9, P = 0.04) than those who were not on anti-tumor necrosis factor. Regarding sexual function, no significant differences were found across patients with IBD and control subjects. Conclusions: Men with Crohn's disease showed a trend toward poorer semen quality than those with ulcerative colitis. Treatment with anti-tumor necrosis factor drugs does not seem to be associated with poor sperm quality. In patients in clinical remission, male sexual function is not affected by IBD.

Palabras clave